Brokerages Expect Denali Therapeutics Inc. (NASDAQ:DNLI) to Post -$0.47 Earnings Per Share

Equities research analysts expect Denali Therapeutics Inc. (NASDAQ:DNLIGet Rating) to announce earnings per share (EPS) of ($0.47) for the current quarter, Zacks reports. Six analysts have made estimates for Denali Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.66) and the highest estimate coming in at $0.04. Denali Therapeutics posted earnings per share of ($0.58) during the same quarter last year, which suggests a positive year over year growth rate of 19%. The business is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Denali Therapeutics will report full-year earnings of ($2.60) per share for the current fiscal year, with EPS estimates ranging from ($2.84) to ($2.15). For the next year, analysts anticipate that the business will post earnings of ($2.46) per share, with EPS estimates ranging from ($3.07) to ($1.03). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Denali Therapeutics.

Denali Therapeutics (NASDAQ:DNLIGet Rating) last issued its quarterly earnings results on Monday, February 28th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.21). The business had revenue of $12.51 million during the quarter, compared to the consensus estimate of $38.16 million. Denali Therapeutics had a negative return on equity of 27.99% and a negative net margin of 597.15%.

Several research analysts recently issued reports on DNLI shares. The Goldman Sachs Group decreased their price target on shares of Denali Therapeutics from $114.00 to $98.00 and set a “buy” rating for the company in a research note on Monday, March 7th. Morgan Stanley reduced their price target on shares of Denali Therapeutics from $99.00 to $91.00 and set an “overweight” rating for the company in a research note on Thursday, January 6th. TheStreet lowered shares of Denali Therapeutics from a “c-” rating to a “d” rating in a research note on Wednesday, March 2nd. Finally, Wedbush reiterated an “outperform” rating on shares of Denali Therapeutics in a research note on Tuesday, March 1st. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $85.88.

Shares of Denali Therapeutics stock traded down $0.93 during trading on Friday, hitting $30.11. The company’s stock had a trading volume of 351,897 shares, compared to its average volume of 463,517. The company has a fifty day simple moving average of $32.75 and a two-hundred day simple moving average of $40.38. The company has a market capitalization of $3.70 billion, a PE ratio of -12.60 and a beta of 1.82. Denali Therapeutics has a 52 week low of $28.76 and a 52 week high of $79.70.

In related news, Director Marc Tessier-Lavigne sold 20,000 shares of the stock in a transaction that occurred on Wednesday, March 23rd. The shares were sold at an average price of $33.83, for a total value of $676,600.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Carole Ho sold 2,918 shares of the stock in a transaction that occurred on Friday, February 11th. The stock was sold at an average price of $34.71, for a total transaction of $101,283.78. The disclosure for this sale can be found here. Insiders have sold 43,210 shares of company stock worth $1,496,386 in the last quarter. Company insiders own 17.00% of the company’s stock.

Large investors have recently modified their holdings of the stock. Baillie Gifford & Co. grew its stake in shares of Denali Therapeutics by 0.3% during the 4th quarter. Baillie Gifford & Co. now owns 15,056,381 shares of the company’s stock worth $671,515,000 after purchasing an additional 46,565 shares during the period. BlackRock Inc. grew its stake in shares of Denali Therapeutics by 7.3% during the 4th quarter. BlackRock Inc. now owns 8,110,822 shares of the company’s stock worth $361,741,000 after purchasing an additional 549,985 shares during the period. Temasek Holdings Private Ltd grew its stake in shares of Denali Therapeutics by 21.7% during the 3rd quarter. Temasek Holdings Private Ltd now owns 5,369,487 shares of the company’s stock worth $270,891,000 after purchasing an additional 959,030 shares during the period. State Street Corp grew its stake in shares of Denali Therapeutics by 8.2% during the 4th quarter. State Street Corp now owns 3,027,571 shares of the company’s stock worth $135,030,000 after purchasing an additional 229,437 shares during the period. Finally, Credit Suisse AG grew its stake in Denali Therapeutics by 0.8% in the 3rd quarter. Credit Suisse AG now owns 1,982,473 shares of the company’s stock valued at $100,015,000 after acquiring an additional 15,965 shares during the period. Institutional investors own 69.15% of the company’s stock.

Denali Therapeutics Company Profile (Get Rating)

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Featured Articles

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.